Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2,
double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with
placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus
Erythematosus (SLE). Study details include:
- Study duration: 36 weeks
- Treatment duration: 24 weeks
- Visit frequency: every 2 weeks